Has Andrew Shorr, MD received payments from drug or device companies?

Yes. Drug and device makers reported $349,010 in general payments to Andrew Shorr, MD across 243 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Andrew Shorr, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Andrew Shorr, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Andrew Shorr, MD

Pulmonary Disease · Washington, DCNPI 1598714438

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Merck at 53.8% of the total. Reporting peaked in 2019 at $177,971 and has fallen 91.9% since, to $14,494 in 2025. Among pulmonary disease clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$349,010in general payments, 2019–2025

Across 243 payments — averaging $1436.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$188K
Pfizer$45K
Tetraphase Pharmaceuticals, Inc.$41K
Shionogi Inc$38K
Bavarian Nordic A/s$12K
Radiometer America, Inc$8K
plus $17K from 10 others

$16,098in research payments, 2019–2025

Across 6 payments — averaging $2683.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$9K
Bavarian Nordic A/s$7K

What the payments were for

Consulting fees$121,15935%
Speaking & faculty fees$156,91645%
Travel & lodging$66,44419%
Food & beverage$3,5881%
Education$9020%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	141	$187,786
Pfizer(2 entities)	18	$44,914
Tetraphase Pharmaceuticals, Inc.	23	$41,283
Shionogi Inc	27	$37,777
Bavarian Nordic A/s	5	$12,120
Radiometer America, Inc	2	$8,352
AbbVie	9	$7,376
Xellia Pharmaceuticals	6	$4,603
La Jolla Pharmaceutical Company	2	$2,841
Meitheal Pharmaceuticals, Inc.	2	$830
Astellas Pharma US Inc	2	$780
Astrazeneca UK Limited	2	$139
Eagle Pharmaceuticals, Inc.	1	$96
Intuitive Surgical	1	$57
Caris MPI, Inc.	1	$35
Astellas Pharma Global Development	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ZERBAXA$62,347
Fetroja$37,419
Xerava$35,305
RECARBRIO$16,643
PREVYMIS$7,720
AVYCAZ$5,194
VANCOMYCIN$4,451
GIAPREZA$2,815
DALVANCE$2,080
CRESEMBA$780

How this compares

$349,010 in reported general payments places this provider in the 95th percentile of 56 pulmonary disease providers in District of Columbia.

See all pulmonary disease providers in District of Columbia →

Medicare billing

Part B allowed, 2024

$87,767

Medicare patients

268

Services billed

526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ambrisentan	12	$61,525
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	55	$40,194
Spiriva RespimatTiotropium Bromide	13	$7,220
Spiriva HandihalerTiotropium Bromide	14	$7,215
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate	14	$2,418
Albuterol Sulfate HfaAlbuterol Sulfate	25	$697

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Washington

Eric AndersonWashington$215K
Anne OdonnellWashington$61K
Andrew LernerWashington$19K
Guillermo GutierrezWashington$14K
Khalil DiabWashington$10K
Lorenzo LeysWashington$9K
Rebecca KrochmalWashington$9K
Steven LernerWashington$6K
Karen FaganWashington$6K
Leslie KingslowWashington$6K

See the full list for District of Columbia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →